S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
NASDAQ:CMPX

Compass Therapeutics (CMPX) Price Target & Analyst Ratings

$3.05
-0.04 (-1.29%)
(As of 05/26/2023 08:46 PM ET)
Compare
Today's Range
$3.03
▼
$3.21
50-Day Range
$2.64
▼
$3.48
52-Week Range
$1.81
▼
$5.65
Volume
256,600 shs
Average Volume
368,939 shs
Market Capitalization
$385.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.05
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Compass Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$9.05
196.72% Upside
High Prediction$10.30
Average Prediction$9.05
Low Prediction$8.00
TypeCurrent
5/29/22 to 5/29/23		1 Month Ago
4/29/22 to 4/29/23		3 Months Ago
2/28/22 to 2/28/23		1 Year Ago
5/29/21 to 5/29/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
8 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$9.05$9.05$9.05$10.00
Predicted Upside196.72% Upside123.61% Upside132.65% Upside252.47% Upside
Get Compass Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.


CMPX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CMPX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Compass Therapeutics Stock vs. The Competition

TypeCompass TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside196.72% Upside1,318.29% Upside196.76% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/16/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$10.00+192.40%
1/31/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$8.00+107.79%
1/26/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$9.00+128.43%
12/16/2022EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$10.30+123.43%
11/16/2022LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$9.00+100.00%
11/10/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$5.00 ➝ $8.00+90.93%
6/22/2022B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Mamtani
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy
(Data available from 5/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CMPX Price Target - Frequently Asked Questions

What is Compass Therapeutics's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Compass Therapeutics stock is Buy based on the current 6 buy ratings for CMPX. The average twelve-month price prediction for Compass Therapeutics is $9.05 with a high price target of $10.30 and a low price target of $8.00. Learn more on CMPX's analyst rating history.

Do Wall Street analysts like Compass Therapeutics more than its competitors?

Analysts like Compass Therapeutics more than other Medical companies. The consensus rating score for Compass Therapeutics is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how CMPX compares to other companies.

Does Compass Therapeutics's stock price have much upside?

According to analysts, Compass Therapeutics's stock has a predicted upside of 123.61% based on their 12-month price targets.

What analysts cover Compass Therapeutics?

Compass Therapeutics has been rated by HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:CMPX) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -